345 related articles for article (PubMed ID: 23919353)
41. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus.
Reker D; Rodrigues T; Schneider P; Schneider G
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4067-72. PubMed ID: 24591595
[TBL] [Abstract][Full Text] [Related]
42. Updates to Binding MOAD (Mother of All Databases): Polypharmacology Tools and Their Utility in Drug Repurposing.
Smith RD; Clark JJ; Ahmed A; Orban ZJ; Dunbar JB; Carlson HA
J Mol Biol; 2019 Jun; 431(13):2423-2433. PubMed ID: 31125569
[TBL] [Abstract][Full Text] [Related]
43. Drug combination therapy increases successful drug repositioning.
Sun W; Sanderson PE; Zheng W
Drug Discov Today; 2016 Jul; 21(7):1189-95. PubMed ID: 27240777
[TBL] [Abstract][Full Text] [Related]
44. Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology.
Wathieu H; Issa NT; Byers SW; Dakshanamurthy S
Curr Pharm Des; 2016; 22(21):3097-108. PubMed ID: 26907947
[TBL] [Abstract][Full Text] [Related]
45. Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets.
Saqib U; Kelley TT; Panguluri SK; Liu D; Savai R; Baig MS; Schürer SC
Front Pharmacol; 2018; 9():1201. PubMed ID: 30405416
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic Potential of Natural Psychoactive Drugs for Central Nervous System Disorders: A Perspective from Polypharmacology.
Oña G; Bouso JC
Curr Med Chem; 2021; 28(1):53-68. PubMed ID: 31830883
[TBL] [Abstract][Full Text] [Related]
47. Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.
Proschak E; Stark H; Merk D
J Med Chem; 2019 Jan; 62(2):420-444. PubMed ID: 30035545
[TBL] [Abstract][Full Text] [Related]
48. PubChem as a source of polypharmacology.
Chen B; Wild D; Guha R
J Chem Inf Model; 2009 Sep; 49(9):2044-55. PubMed ID: 19708682
[TBL] [Abstract][Full Text] [Related]
49. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it.
Kell DB
FEBS J; 2013 Dec; 280(23):5957-80. PubMed ID: 23552054
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic polypharmacology: A new frontier for epi-drug discovery.
Tomaselli D; Lucidi A; Rotili D; Mai A
Med Res Rev; 2020 Jan; 40(1):190-244. PubMed ID: 31218726
[TBL] [Abstract][Full Text] [Related]
51. Drug promiscuity: Exploring the polypharmacology potential of 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones as an inhibitor of the 'god father' of immune checkpoint.
Soremekun OS; Olotu FA; Agoni C; Soliman MES
Comput Biol Chem; 2019 Jun; 80():433-440. PubMed ID: 31146119
[TBL] [Abstract][Full Text] [Related]
52. Shifting from the single to the multitarget paradigm in drug discovery.
Medina-Franco JL; Giulianotti MA; Welmaker GS; Houghten RA
Drug Discov Today; 2013 May; 18(9-10):495-501. PubMed ID: 23340113
[TBL] [Abstract][Full Text] [Related]
53. The role of fragment-based and computational methods in polypharmacology.
Bottegoni G; Favia AD; Recanatini M; Cavalli A
Drug Discov Today; 2012 Jan; 17(1-2):23-34. PubMed ID: 21864710
[TBL] [Abstract][Full Text] [Related]
54. Ligand-receptor interaction platforms and their applications for drug discovery.
Fang Y
Expert Opin Drug Discov; 2012 Oct; 7(10):969-88. PubMed ID: 22860803
[TBL] [Abstract][Full Text] [Related]
55. In silico drug repositioning: what we need to know.
Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
[TBL] [Abstract][Full Text] [Related]
56. Network pharmacology: the next paradigm in drug discovery.
Hopkins AL
Nat Chem Biol; 2008 Nov; 4(11):682-90. PubMed ID: 18936753
[TBL] [Abstract][Full Text] [Related]
57. Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem.
Lim H; Gray P; Xie L; Poleksic A
Sci Rep; 2016 Dec; 6():38860. PubMed ID: 27958331
[TBL] [Abstract][Full Text] [Related]
58. Drug discovery and the use of computational approaches for infectious diseases.
Marhöfer RJ; Oellien F; Selzer PM
Future Med Chem; 2011 Jun; 3(8):1011-25. PubMed ID: 21707402
[TBL] [Abstract][Full Text] [Related]
59. Drug repurposing and adverse event prediction using high-throughput literature analysis.
Deftereos SN; Andronis C; Friedla EJ; Persidis A; Persidis A
Wiley Interdiscip Rev Syst Biol Med; 2011; 3(3):323-34. PubMed ID: 21416632
[TBL] [Abstract][Full Text] [Related]
60. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs.
Hu Y; Bajorath J
J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
